The ASCO Post: Professor Anthony Moorman on ALL June 2020

Anthony Moorman, PhD, of Newcastle University, discusses preliminary data showing high-risk patients with acute lymphoblastic leukemia and ABL-class mutations may have improved outcomes when a tyrosine kinase inhibitor is added to chemotherapy (Abstract S117)

Anthony Moorman, PhD, on ALL: Improving Outcomes With a Tyrosine Kinase Inhibitor Plus Chemotherapy from Harborside on Vimeo.

Last modified: Tue, 11 Aug 2020 10:24:00 BST